SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
RNAi
An SI Board Since May 2003
Posts SubjectMarks Bans
671 52 0
Emcee:  tuck Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
596<b>Blood 'fingerprints' for cancer</b> Wed Sep 3 11:18:13 2idos-9/5/2008
595Clearly, getting off target immune responses would almost certainly be undesirabIan@SI-9/3/2008
594Tuck: Protiva, mentioned in article, merged with Tekmira (Yahoo symbol is TKM.TOBulbaMan-9/3/2008
593Interesting, Ian. Wonder if this explains any of the off-target effects first dtuck-9/3/2008
592perhaps a big oops... Public release date: 2-Sep-2008 Contact: Vicki Cohn vcohIan@SI-9/2/2008
591<i>Some speculations about potential side effects:</i> <b>Expidos-8/28/2008
590BIOMARKERS <b>Finding the needle in the haystack</b> By Safia Alidos-8/23/2008
589Contact: Alyssa Kneller public_affairs@hms.harvard.edu 617-432-0442 Harvard Mediidos-8/7/2008
588ALNY revoked MRNA’s RNAi license for the TNF-alpha pathway because ALNY says MRNDewDiligence_on_SI-8/6/2008
587<b>Thousands of proteins affected by miRNAs</b> Published online 30idos-7/31/2008
586Silence Therapeutics to Receive $1.9m Milestone Payment as 2008-07-30 12:03:45.7A.J. Mullen-7/30/2008
585Feuerstein on MRNA (formerly NSTK): siliconinvestor.comDewDiligence_on_SI-7/12/2008
584Silence Therapeutics Announces Successful Opposition of Glover Patent Friday JulA.J. Mullen-7/11/2008
583Alnylam Provides Update on "Glover" Patent Thursday July 10, 5:00 pm EA.J. Mullen-7/10/2008
582Press Release Source: Silence Therapeutics plc FDA Approves Quark IND for DGFiA.J. Mullen-6/25/2008
581Dueling perspectives on the new MDRNA blog.seattlepi.nwsource.comMike McFarland-6/19/2008
580At Beyond Genome, Dicerna Calls Virology, Oncology, Metabolic Disease Focus AreMike McFarland-6/12/2008
579Investing in miRNA: Beware the Hype, Follow the Money seekingalpha.com by: Ohad A.J. Mullen-6/10/2008
578Dicerna article bizjournals.com and back to the blog rnaitherapeutics.blogspot.Mike McFarland-6/2/2008
577fun to see the list of sponsors beyondgenome.com For instance Dicerna takes itsMike McFarland-6/2/2008
576My comments would be similar to those that you made on Investorhub - that instabA.J. Mullen-6/2/2008
575<i>I've seen worse slides, but still complicated.</i> LOL––my hDewDiligence_on_SI-6/1/2008
574I've seen worse slides, but still complicated. rnajournal.org I'm so fMike McFarland-6/1/2008
573Thanks again. What is your own opinion on this matter?DewDiligence_on_SI-6/1/2008
572Ah, then maybe a later post--the fifth paragraph here rnaitherapeutics.blogspot.Mike McFarland-6/1/2008
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News